請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/74449
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 李明學(Ming-Shyue Lee) | |
dc.contributor.author | Yu-Kuang Fan | en |
dc.contributor.author | 范有光 | zh_TW |
dc.date.accessioned | 2021-06-17T08:36:25Z | - |
dc.date.available | 2025-01-26 | |
dc.date.copyright | 2021-02-23 | |
dc.date.issued | 2021 | |
dc.date.submitted | 2021-01-26 | |
dc.identifier.citation | [1] Chae YK, Pan AP, Davis AA, Patel SP, Carneiro BA, Kurzrock R, Giles FJ: Path toward Precision Oncology: Review of Targeted Therapy Studies and Tools to Aid in Defining 'Actionability' of a Molecular Lesion and Patient Management Support. Mol Cancer Ther 2017, 16:2645-55. [2] Lee YT, Tan YJ, Oon CE: Molecular targeted therapy: Treating cancer with specificity. Eur J Pharmacol 2018, 834:188-96. [3] Lavanya V MAAA, Neesar Ahmed, Arun K. Rishi and Shazia Jamal: Small molecule inhibitors as emerging cancer therapeutics. Integrative Cancer Science and Therapeutics 2014, 1. [4] Saijo N: Progress in cancer chemotherapy with special stress on molecular-targeted therapy. Jpn J Clin Oncol 2010, 40:855-62. [5] Padma VV: An overview of targeted cancer therapy. Biomedicine (Taipei) 2015, 5:19. [6] De Palma M, Hanahan D: The biology of personalized cancer medicine: facing individual complexities underlying hallmark capabilities. Mol Oncol 2012, 6:111-27. [7] Hatzidaki E, Parsonidis P, Apostolou P, Daikopoulou V, Papasotiriou I: Novel small molecule decreases cell proliferation, migration, clone formation, and gene expression through ERK inhibition in MCF-7 and MDA-MB-231 breast cancer cell lines. Anticancer Drugs 2019, 30:618-27. [8] Ma X, Tian J, Yang X, Qin C: Molecular imaging in tumor angiogenesis and relevant drug research. Int J Biomed Imaging 2011, 2011:370701. [9] Leary A, Johnston SR: Small molecule signal transduction inhibitors for the treatment of solid tumors. Cancer Invest 2007, 25:347-65. [10] Plati J, Bucur O, Khosravi-Far R: Apoptotic cell signaling in cancer progression and therapy. Integr Biol (Camb) 2011, 3:279-96. [11] Zhong S, Jeong JH, Chen Z, Chen Z, Luo JL: Targeting Tumor Microenvironment by Small-Molecule Inhibitors. Transl Oncol 2020, 13:57-69. [12] Alimbetov D, Askarova S, Umbayev B, Davis T, Kipling D: Pharmacological Targeting of Cell Cycle, Apoptotic and Cell Adhesion Signaling Pathways Implicated in Chemoresistance of Cancer Cells. Int J Mol Sci 2018, 19. [13] Wu P, Nielsen TE, Clausen MH: Small-molecule kinase inhibitors: an analysis of FDA-approved drugs. Drug Discov Today 2016, 21:5-10. [14] Ann Lin CJG, Ann Palladino, Kristen M. John, Connor Abramowicz,, Monet Lou Yuan ELS, Devon A. Lukow, Luwei Liu, Alexander R. Chait,, Zachary C. Galluzzo CT, Jason M. Sheltzer: Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials. SCIENCE TRANSLATIONAL MEDICINE 2019, 11. [15] Mirsafian H, Ripen AM, Leong WM, Chear CT, Bin Mohamad S, Merican AF: Transcriptome profiling of monocytes from XLA patients revealed the innate immune function dysregulation due to the BTK gene expression deficiency. Sci Rep 2017, 7:6836. [16] HENDRIKS AMaRW: Role of Bruton’s Tyrosine Kinase in B Cell Development. Developmental Immunology 2001, 8(3-4):171-81. [17] Pal Singh S, Dammeijer F, Hendriks RW: Role of Bruton's tyrosine kinase in B cells and malignancies. Mol Cancer 2018, 17:57. [18] Daisuke Hata YK, Naoki Inagaki, Chris S. Lantz,, Toshio Kitamura WNKMM-Y, Toru Miura WH, Stephen E. Hartman, Libo Yao,, Hiroichi Nagai AEG, Frederick W. Alt,, Stephen J. Galli ONW, andToshiaki Kawakami: Involvement of Bruton’s Tyrosine Kinase in FceRI-dependent Mast Cell Degranulation and Cytokine Production. J Exp Med 1998, 187:1235–47. [19] Rule S, Chen RW: New and emerging Bruton tyrosine kinase inhibitors for treating mantle cell lymphoma - where do they fit in? Expert Rev Hematol 2018, 11:749-56. [20] Aalipour A, Advani RH: Bruton's tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: focus on ibrutinib. Ther Adv Hematol 2014, 5:121-33. [21] de Weerdt I, Koopmans SM, Kater AP, van Gelder M: Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach. Haematologica 2017, 102:1629-39. [22] Barf T, Covey T, Izumi R, van de Kar B, Gulrajani M, van Lith B, van Hoek M, de Zwart E, Mittag D, Demont D, Verkaik S, Krantz F, Pearson PG, Ulrich R, Kaptein A: Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile. J Pharmacol Exp Ther 2017, 363:240-52. [23] Kang JY, Kang N, Yang YM, Hong JH, Shin DM: The Role of Ca(2+)-NFATc1 Signaling and Its Modulation on Osteoclastogenesis. Int J Mol Sci 2020, 21. [24] Seda V, Mraz M: B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells. Eur J Haematol 2015, 94:193-205. [25] Dubovsky JA, Beckwith KA, Natarajan G, Woyach JA, Jaglowski S, Zhong Y, Hessler JD, Liu TM, Chang BY, Larkin KM, Stefanovski MR, Chappell DL, Frissora FW, Smith LL, Smucker KA, Flynn JM, Jones JA, Andritsos LA, Maddocks K, Lehman AM, Furman R, Sharman J, Mishra A, Caligiuri MA, Satoskar AR, Buggy JJ, Muthusamy N, Johnson AJ, Byrd JC: Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood 2013, 122:2539-49. [26] Ramsay AG, Johnson AJ, Lee AM, Gorgun G, Le Dieu R, Blum W, Byrd JC, Gribben JG: Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest 2008, 118:2427-37. [27] Gabrilovich DI, Nagaraj S: Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009, 9:162-74. [28] Molina-Cerrillo J, Alonso-Gordoa T, Gajate P, Grande E: Bruton's tyrosine kinase (BTK) as a promising target in solid tumors. Cancer Treat Rev 2017, 58:41-50. [29] Metzler JM, Burla L, Fink D, Imesch P: Ibrutinib in Gynecological Malignancies and Breast Cancer: A Systematic Review. Int J Mol Sci 2020, 21. [30] Wu J, Zhang M, Liu D: Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor. J Hematol Oncol 2016, 9:21. [31] Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018, 68:394-424. [32] Rawla P: Epidemiology of Prostate Cancer. World J Oncol 2019, 10:63-89. [33] Tombal B: Non-metastatic CRPC and asymptomatic metastatic CRPC: which treatment for which patient? Ann Oncol 2012, 23 Suppl 10:x251-8. [34] Amaral TM, Macedo D, Fernandes I, Costa L: Castration-resistant prostate cancer: mechanisms, targets, and treatment. Prostate Cancer 2012, 2012:327253. [35] Fizazi K, Carducci M, Smith M, Damião R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, Jiang Q, Tadros S, Dansey R, Goessl C: Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. The Lancet 2011, 377:813-22. [36] Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S, Davis ID, de Bono JS, Evans CP, Fizazi K, Joshua AM, Kim CS, Kimura G, Mainwaring P, Mansbach H, Miller K, Noonberg SB, Perabo F, Phung D, Saad F, Scher HI, Taplin ME, Venner PM, Tombal B, Investigators P: Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014, 371:424-33. [37] Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Flechon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS, Investigators A: Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012, 367:1187-97. [38] Yang S, Huang FK, Huang J, Chen S, Jakoncic J, Leo-Macias A, Diaz-Avalos R, Chen L, Zhang JJ, Huang XY: Molecular mechanism of fascin function in filopodial formation. J Biol Chem 2013, 288:274-84. [39] Van Audenhove I, Denert M, Boucherie C, Pieters L, Cornelissen M, Gettemans J: Fascin Rigidity and L-plastin Flexibility Cooperate in Cancer Cell Invadopodia and Filopodia. J Biol Chem 2016, 291:9148-60. [40] SAMUEL L. JONES JW, CHRISTOPH W. TURCK, AND ERIC J. BROWN: A role for the actin-bundling protein L-plastin in the regulation of leukocyte integrin function. Proc Natl Acad Sci USA 1998, 95:9331–6. [41] Delanote V, Vanloo B, Catillon M, Friederich E, Vandekerckhove J, Gettemans J: An alpaca single-domain antibody blocks filopodia formation by obstructing L-plastin-mediated F-actin bundling. FASEB J 2010, 24:105-18. [42] Morley SC: The actin-bundling protein L-plastin: a critical regulator of immune cell function. Int J Cell Biol 2012, 2012:935173. [43] Janji B, Giganti A, De Corte V, Catillon M, Bruyneel E, Lentz D, Plastino J, Gettemans J, Friederich E: Phosphorylation on Ser5 increases the F-actin-binding activity of L-plastin and promotes its targeting to sites of actin assembly in cells. J Cell Sci 2006, 119:1947-60. [44] Ishida H, Jensen KV, Woodman AG, Hyndman ME, Vogel HJ: The Calcium-Dependent Switch Helix of L-Plastin Regulates Actin Bundling. Sci Rep 2017, 7:40662. [45] Yuziro Namba Mat, Y ouliZ u,K atsuya Shigesada,an d KoscakM aruyama: Human T Cell L-Plastin Bundles Actin Filaments in a Calcium-Dependent Manner. J Biochem 1992, 112:503-7. [46] Balta E, Hardt R, Liang J, Kirchgessner H, Orlik C, Jahraus B, Hillmer S, Meuer S, Hubner K, Wabnitz GH, Samstag Y: Spatial oxidation of L-plastin downmodulates actin-based functions of tumor cells. Nat Commun 2019, 10:4073. [47] Ching-Shwun Lin$ TP, Zong Ping Chen$, and John Leavitt$$: Human Plastin Genes. THE JOURNAL OF BIOLOGICAL CHEMISTRY 1993. [48] Taesun Park ZPC, and John Leavitt: Activation of the Leukocyte Plastin Gene Occurs in Most Human Cancer Cells. CANCER RESEARCH 1994, 54:1775-178],. [49] Otsuka M, Kato M, Yoshikawa T, Chen H, Brown EJ, Masuho Y, Omata M, Seki N: Differential expression of the L-plastin gene in human colorectal cancer progression and metastasis. Biochem Biophys Res Commun 2001, 289:876-81. [50] Shinomiya H: Plastin family of actin-bundling proteins: its functions in leukocytes, neurons, intestines, and cancer. Int J Cell Biol 2012, 2012:213492. [51] Chen C, Cai Q, He W, Lam TB, Lin J, Zhao Y, Chen X, Gu P, Huang H, Xue M, Liu H, Su F, Huang J, Zheng J, Lin T: AP4 modulated by the PI3K/AKT pathway promotes prostate cancer proliferation and metastasis of prostate cancer via upregulating L-plastin. Cell Death Dis 2017, 8:e3060. [52] Riplinger SM: Metastasis of prostate cancer and melanoma cells in a preclinical in vivo mouse model is enhanced by L-plastin expression and phosphorylation. Mol Cancer 2014. [53] Taesun Park ZPC, and John Leavitt: Activation of the Leukocyte Plastin Gene Occurs in Most Human Cancer Cells. CANCER RESEARCH 1994. [54] Hamasy A, Wang Q, Blomberg KE, Mohammad DK, Yu L, Vihinen M, Berglof A, Smith CI: Substitution scanning identifies a novel, catalytically active ibrutinib-resistant BTK cysteine 481 to threonine (C481T) variant. Leukemia 2017, 31:177-85. [55] Ginsburg GS, Phillips KA: Precision Medicine: From Science To Value. Health Aff (Millwood) 2018, 37:694-701. [56] Hodson R: Precision medicine. Nature 2016, pageS49(2016):537,. [57] Rudmann DG: On-target and off-target-based toxicologic effects. Toxicol Pathol 2013, 41:310-4. [58] Wynn ML, Ventura AC, Sepulchre JA, Garcia HJ, Merajver SD: Kinase inhibitors can produce off-target effects and activate linked pathways by retroactivity. BMC Syst Biol 2011, 5:156. [59] Liu Q, Sabnis Y, Zhao Z, Zhang T, Buhrlage SJ, Jones LH, Gray NS: Developing irreversible inhibitors of the protein kinase cysteinome. Chem Biol 2013, 20:146-59. [60] Singh J, Petter RC, Baillie TA, Whitty A: The resurgence of covalent drugs. Nat Rev Drug Discov 2011, 10:307-17. [61] Jiao Q, Bi L, Ren Y, Song S, Wang Q, Wang YS: Advances in studies of tyrosine kinase inhibitors and their acquired resistance. Mol Cancer 2018, 17:36. [62] Zhou Y, Lu H, Yang M, Xu C: Adverse drug events associated with ibrutinib for the treatment of elderly patients with chronic lymphocytic leukemia: A systematic review and meta-analysis of randomized trials. Medicine (Baltimore) 2019, 98:e16915. [63] Ahn IE: Cardiovascular adverse events of ibrutinib. Blood 2019, 134:1881-2. [64] Berglof A, Hamasy A, Meinke S, Palma M, Krstic A, Mansson R, Kimby E, Osterborg A, Smith CI: Targets for Ibrutinib Beyond B Cell Malignancies. Scand J Immunol 2015, 82:208-17. [65] Cheng-Han Yu C-CC, Hsin-Fang Tu, Wei-Chieh Huang, Ya-Yeh Ho,, Kay-Hooi Khoo M-SLaG-DC: Antibody-assisted target identification reveals afatinib, an EGFR covalent inhibitor, down-regulating ribonucleotide reductase. Oncotarget 2018, Vol. 9,:pp: 21512-29. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/74449 | - |
dc.description.abstract | 標靶治療為針對病人臨床病徵、基因定序及疾病的致病機制做治療的醫療策略,而在此當中標靶藥物的專一性尤為重要,若標靶藥物有其他非主目標之標的則會影響其治療效率、藥物毒性以及副作用,因此瞭解完整的藥物標的可以進一步理解藥物的作用機制及使用時機。在實驗室先前的研究當中,我們發現Bruton kinase (BTK) inhibitor (BI1) 可作用於非原標靶蛋白之細胞骨架蛋白L-plastin,並抑制其功能。在前列腺癌細胞CWR22Rv1當中表現L-plastin蛋白可以增強其侵襲能力,而此一增強可以被BI1作用後抑制。此外,L-plastin的束肌絲(actin bundle)功能也可以被BI1降低。這些結果都顯示了BI1對L-plastin的抑制性,但其作用機制尚不明確。在本論文當中,我們使用了點突變及免疫沉澱法發現了BI1的作用於L-plastin第101個胺基酸半胱胺酸(Cys)並形成共價鍵結合,而在表現了L-plastin並增強侵襲能力的前列腺癌細胞中,若將表現的L-plastin第101號位點突變成絲氨酸(Ser)會使細胞的侵襲能力不再被BI1影響。在束肌絲實驗中,若使用101號位點突變的L-plastin重組蛋白進行實驗,可以發現BI1也不再能夠降低其功能。另一方面,在BI1的作用之下,在免疫螢光染色下可以發現前列腺癌細胞的偽足生成明顯的降低,也與前項L-plastin功能被抑制的結果相符。結合先前論文對於L-plastin第101號位點為調控其功能的重要中樞這點,我們認為BI1對於L-plastin功能的影響非常大,並可以透過其影響癌細胞的侵襲與移動。這些結果證明了L-plastin為BI1的重要標的蛋白,而在各癌症當中表現量都升高的L-plastin也具有作為未來小分子藥物標的的潛力。 | zh_TW |
dc.description.abstract | A targeted drug has been estimated to have at least 6.3 targets and implicated that each drug exhibits its target profiles. If the target profile of each drug and the detailed drug action on the disease treatment can be revealed, the information will provide a precision guideline for a correct use of a drug on the right group of patients and improve precision medicine. In our previous study, we found that Bruton kinase inhibitor BI1 had an additional target, L-plastin, which has an actin bundling activity. BI1 could decrease prostate cancer CWR22Rv1 cell invasion and inhibit the actin bundling activity of L-plastin. However, the mechanism how BI1 targeted L-plastin remained largely unknown. In this study, I found that BI1 could covalently bind to the amino acid residue of cysteine 101 in the regulation helix domain of L-plastin. Moreover, BI1 could reduce the formation of pseudopodia in prostate cancer PC3 cells and thus decrease the cell invasion capability. The results together indicate that BI1 can target to L-plastin via a covalent linkage on L-plastin’s amino acid residue of cysteine 101 and results in inhibition of L-plastin activity, pseudopodia formation and prostate cancer cell motility. Our findings further suggest that BI1 has a repurposing potential against prostate cancer. | en |
dc.description.provenance | Made available in DSpace on 2021-06-17T08:36:25Z (GMT). No. of bitstreams: 1 U0001-2001202114195500.pdf: 3247803 bytes, checksum: 3fadf19f58b56f0c6b5b0b23b98ba3a4 (MD5) Previous issue date: 2021 | en |
dc.description.tableofcontents | 致謝 1 中文摘要 2 Abstract 3 Chapter 1. Introduction 7 1. Precision medicine 8 2. Bruton kinase and Bruton kinase inhibitor 9 3. BTK inhibitor in solid tumor 10 4. Prostate cancer 11 5. L-plastin 12 6. L-plastin and prostate cancer 13 7. Purpose of this study 14 Chapter 2. Materials and Methods 15 Chapter 3. Results 32 1. The interaction of L-plastin with BI1 33 2. L-plastin expression levels in different prostate cancer cell lines and prostate cancer tissues. 33 3. Effects of BI1 on the cytotoxicity of prostate cancer PC3 cells 34 4. Examination of the effects of BI1 on prostate cancer PC3 cell invasion 35 5. Analysis of the effects of BI1 on the L-plastin protein levels in PC3 cells 35 6. Identification of BI1-targeted amino acid residue on L-plastin in cells 35 7. Effect of BI1 on wild-type and C101S L-plastin-affected prostate cancer cell invasion 37 8. Examination of the effect of BI1 on the actin bundling activity of purified wild-type and C101S L-plastin recombinant proteins. 38 9. Exploration of BI1 effects on the pseudopodia formation of PC3 cells 39 Chapter 4. Discussion 41 Chapter 5. Figures 46 Chapter 6. References 66 | |
dc.language.iso | zh-TW | |
dc.title | 探討BTK抑制劑BI1對前列腺癌細胞的移動力及型態之影響 | zh_TW |
dc.title | The effect of BTK inhibitor BI1 on prostate cancer motility and cell morphology | en |
dc.type | Thesis | |
dc.date.schoolyear | 109-1 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 張震東(Geen-Dong Chang),黃祥博(Hsiang-Po Huang),吳尚儒(Shang-Ju Wu) | |
dc.subject.keyword | BI1,L-plastin,前列腺癌,侵襲能力,偽足, | zh_TW |
dc.subject.keyword | BI1,L-plastin,prostate cancer,invasion,pseudopodia, | en |
dc.relation.page | 70 | |
dc.identifier.doi | 10.6342/NTU202100100 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2021-01-27 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 生物化學暨分子生物學研究所 | zh_TW |
顯示於系所單位: | 生物化學暨分子生物學科研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
U0001-2001202114195500.pdf 目前未授權公開取用 | 3.17 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。